Anti-human cd45rc antibodies and uses thereof
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Universite De Nantes, Centre Hospitalier Universitaire De Nantes
InventorsCarole GUILLONNEAU, Ignacio ANEGON
Life of this patent
Estimating the term…
Abstract
Isolated anti-human CD45RC antibodies or binding fragments thereof, nucleic acids and expression vector encoding the same, compositions including the same, and uses thereof as medicaments, including for the prevention and/or treatment of CD45RChigh-related diseases (including autoimmune diseases, undesired immune responses, monogenic diseases, and lymphoma or cancer), in particular for use in preventing and/or treating graft-versus-host disease (GVHD).
Claims21
1-15. (canceled)
An isolated anti-human CD45RC antibody or binding fragment thereof, wherein said antibody or binding fragment thereof comprises:
- (a) a heavy chain variable region (HCVR) which comprises the following three complementary-determining regions (CDRs):
- (i) VH-CDR1 of sequence SEQ ID NO:
- 1;
- (ii) VH-CDR2 with a sequence selected from the group consisting of sequences SEQ ID NOs:
- 4, 5, 6, 7_8, 9, 10, 11, 100, 116, 117, 118 and 119;
- and
- (iii) VH-CDR3 of sequence SEQ ID NO:
- 3;
- and
- (b) a light chain variable region (LCVR) which comprises the following three CDRs:
- (i) VL-CDR1 with a sequence selected from the group consisting of sequences SEQ ID NO:
- 15 (SASSSVS-X12-YMH) and SEQ ID NO:
- 18 (RASSSVS-X12-YMH), wherein X12 is absent or is selected from the group consisting of Asn (N), Ser (S) and Gly (G);
- (ii) VL-CDR2 with a sequence selected from the group consisting of sequences SEQ ID NOs:
- 16, 19, 20, 22, 111, 120 and 127;
- and
- (iii) VL-CDR3 with a sequence selected from the group consisting of sequences SEQ ID NO:
- 17 and 21.
Dependencies are inferred from the claim text.